These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 907841)

  • 21. Extreme thrombocytosis and cardiovascular surgery: risks and management.
    Natelson EA
    Tex Heart Inst J; 2012; 39(6):792-8. PubMed ID: 23304015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of Highvolume Platelet Reduction Therapy on White Blood Cell Count and Hemoglobin Level in Patients with Thrombocytosis].
    Wu YJ; Wu Y; Li HS; Chen BC; Liu Y; Wu YQ; Liang SY; Liang MQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1607-1611. PubMed ID: 31607320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary thrombocythemia: a current perspective.
    Mughal TI
    Stem Cells; 1995 Jul; 13(4):355-9. PubMed ID: 7549894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-year incidence of thrombocytosis and the effect on heparin dose response and heparin requirements.
    Gayoso JM
    J Extra Corpor Technol; 1999 Dec; 31(4):184-90. PubMed ID: 10915475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic cytapheresis using the Fenwal CS-3000 blood cell separator.
    Steeper TA; Smith JA; McCullough J
    Vox Sang; 1985; 48(4):193-200. PubMed ID: 3984305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bleeding and thrombosis in the myeloproliferative disorders.
    Schafer AI
    Blood; 1984 Jul; 64(1):1-12. PubMed ID: 6375757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Primary thrombocytosis and plateletpheresis--2 cases].
    Maeda H; Sueyoshi A; Iwanaga T; Horiuchi A
    Rinsho Ketsueki; 1982 Oct; 23(10):1651-5. PubMed ID: 7154264
    [No Abstract]   [Full Text] [Related]  

  • 28. Rapid reduction of platelet count in essential hemorrhagic thrombocythemia by discontinuous flow plateletpheresis.
    Younger J; Umlas J
    Am J Med; 1978 Apr; 64(4):659-61. PubMed ID: 565590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
    Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
    Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversible acute sensorineural hearing loss associated with essential thrombocytosis.
    Grisell DL; Mills GM
    Arch Intern Med; 1986 Sep; 146(9):1813. PubMed ID: 3753122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful microsurgical tissue transfer in a patient with postsplenectomy thrombocytosis treated with platelet-phoresis.
    Hsiao HT; Ou SY
    J Reconstr Microsurg; 1997 Nov; 13(8):555-8. PubMed ID: 9401983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis.
    Yataganas X; Meletis J; Plata E; Viniou N; Deligiannis F; Tsekoura C; Voscaridou E; Boussiotis V; Rombos J; Vayopoulos G
    Eur J Cancer; 1991; 27 Suppl 4():S69-71. PubMed ID: 1799484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet apheresis for digital gangrene due to thrombocytosis in chronic myeloid leukaemia.
    Win N; Mitchell DC
    Clin Lab Haematol; 2001 Feb; 23(1):65-6. PubMed ID: 11422234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematologic Conditions: Platelet Disorders.
    Mumford J; Flanagan B; Keber B; Lam L
    FP Essent; 2019 Oct; 485():32-43. PubMed ID: 31613566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mechanical plasmapheresis by means of the Haemonetics-ultralite- plasma collection system: 2. Generation of platelet-rich plasma].
    Richter E; Pawlow I; Matthes G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(1):127-33. PubMed ID: 1695166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plateletpheresis using the haemonetics model 30 cell separator.
    Nusbacher J; Scher ML; MacPherson JL
    Vox Sang; 1977 Jul; 33(1):9-15. PubMed ID: 883246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plateletpheresis in primary thrombocythemia].
    Suzuki K; Asano Y; Yokoyama S; Tomoyasu S; Nunogami N
    Rinsho Ketsueki; 1982 Oct; 23(10):1661-7. PubMed ID: 7154265
    [No Abstract]   [Full Text] [Related]  

  • 39. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
    Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
    Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
    Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
    Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.